Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 8 Feb 2018

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

janssen biotech theravance bowel inflammation

News and Trends 8 Feb 2018

Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug

Janssen Biotech and Theravance Biopharma will develop together a drug to treat bowel inflammation diseases like ulcerative colitis and Crohn’s disease. Janssen Biotech has set its eyes on a drug candidate being developed by the Irish Theravance Biopharma. Both have entered an agreement to co-develop and commercialize the drug. In exchange, Theravance is getting $100M (€82M) […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Feb 2018

January Has Been the Best Month Ever for Biotech in Spain

Biotech in Spain has kicked off 2018 setting a record for the number of acquisitions and fundraisings and their total value combined. Early in January, the Japanese big pharma Takeda announced its intention to acquire TiGenix for €520M. The cell therapy biotech was born in 2011 as a merger of Belgian TiGenix and Spanish Cellerix, […]

February 7, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Deconstructing patterns exhibition francis crick institute

News and Trends 3 Feb 2018

Deconstructing Patterns: First Science and Art Exhibition Opens at the Francis Crick Institute

Deconstructing patterns, the first exhibition of its kind at the Francis Crick Institute, is the result of months of collaborations between scientists and artists. I got a chance to see it at the opening earlier this week. The new exhibition at the Francis Crick Institute puts into perspective the groundbreaking research happening in the scientists’ […]

February 3, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2018

Update: Pocket Device makes its Debut in Whole Human Genome Sequencing

Update (30/01/2018): Oxford Nanopore has published a study in Nature Biotechnology outlining the first use of its pocket MinION device to sequence a human genome. The device was able to read sequences of DNA that are “hundreds of times larger than usual,” helping scientists better reconstruct the whole genome sequence. MinION costs less than $1,000 and […]

January 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

biology art berlin central station novozymes

News and Trends 27 Jan 2018

Biology and Art Take Over the Berlin Central Station

The art installation Relationscape connected many Berlin commuters with the future of biology at the capital’s central station. This week, the daily commuters of the German capital got a chance to come face to face with the world of biology. At the entrance of the Berlin Central Station, a huge building made of steel, glass […]

January 27, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jan 2018

Update: Bionic Implant Restores Vision in a Human for the First Time

Update (26/01/2018): A first patient was implanted with Pixium Vision’s PRIMA bionic device. A month after implantation, the device was activated and the patient, who suffered from severe vision loss due to age-related macular degeneration (AMD), reported “a first perception of light from the central zone where there was none previously,” according to principal investigator Dr. […]

January 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jan 2018

PharmaMar Stock Crashes After Failed Ovarian Cancer Study

PharmaMar’s cancer drug Zepsyre has failed to prove more effective than chemo to treat ovarian cancer in Phase III, leading to a big hit to its stock. Based in Madrid, PharmaMar develops cancer drugs derived from marine organisms. Unfortunately, one of these compounds, lurbinectedin (Zepsyre), has failed to show better efficacy in treating ovarian cancer than chemotherapy in […]

January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jan 2018

Abcam Will Start Selling Over 700 Antibodies from Roche

Abcam and Roche have entered an agreement that will let Abcam sell 760 new antibodies to researchers worldwide through its online platform. Inspired by Amazon, Abcam has become one of Europe’s biggest biotechs by building a platform to make it easier for researchers to order the antibodies they need for their experiments. A new deal with […]

January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

origin of life bioluminescence protocell

More News! 20 Jan 2018

These Artists Recreate the Origins of Life with Bioluminescence

Evelina Domnitch and Dmitry Gelfand explore the origin of life by creating protocell bioluminescence that evokes the early forms of life on Earth. The origin of life is still a bit of a mystery. Scientists have narrowed it down to a series of processes that must have occurred billions of years ago for life to […]

January 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Jan 2018

France Gets Ready to Test CAR-Treg Cells to Avoid Transplant Rejection

TxCell has received a €1.2 loan from Bpifrance to complete preclinical trials with its CAR-Treg technology for transplant rejection and start human testing. French biotech TxCell is finalizing the preparations to take its first cell therapy to clinical trials. The treatment, called HLA-A2 CAR-Treg, is intended for the prevention of chronic rejection after organ transplantation. […]

January 18, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 18 Jan 2018

First Patient Successfully Implanted with Heart Valve Replacement Device

French company Kephalios has successfully implanted a new adjustable device to repair a heart valve defect in a human patient for the first time. The first of five patients in a clinical trial at the Vienna General Hospital has received an implant designed to repair mitral valve regurgitation. This disease causes the mitral valve to not close properly […]

January 18, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us